Aurinia Pharmaceuticals Q3 2026 earnings

AUPH · 2026-10-30 08:03 BMO ET · 8-K on SEC · 10-Q on SEC

Revenue and net income grew for the nine months, but Q3 net income and EPS declined sequentially despite higher revenue.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$83.7M+14%—Ex. 99.1

Revenue breakdown

SegmentActualYoYShare of revenueNote
Net product sales$79.4M+12%95%LUPKYNIS
License, collaboration and royalty revenue$4.3M+54%5%—

Margins and costs

  • Gross margin 90.1% (prior 88.8%, change +1.3 pp)
  • Operating expenses $48.3M (+10.7% YoY)
  • One-offs in the quarter Restructuring $0 (vs $1.6M in prior year); Other (income) expense, net $1,267 (vs $929)
  • Effective tax rate 18.1% (prior-year 1.3%, year-to-date 21.2%)
  • Non-GAAP bridge Deferred income tax, share-based compensation, amortization and depreciation, foreign exchange, net amortization of premiums and discounts, other

KPIs

MetricActualPrior quarterPrior yearChange
Cash, cash equivalents and restricted cash$46.1M$179.8M$44.2M-74.4%
Short-term investments$440.7M$263.3M$45.5M+67.5%
Total assets$825.7M$792.3M$751.6M+4.2%
Total revenue (9M)$244.6M$160.9M$205.9M+18.8%
Net income (9M)$103.5M$71.8M$76.4M+35.5%

Guidance

MetricGuidePrior guideChange
Total revenue 2026$325M to $330M$315M to $325M+1.0 pp to +1.5 pp
Net product sales 2026$310M to $315M$305M to $315M+0.5 pp

What drove it

  • Revenue story Total revenue grew 14% YoY to $83.7M, driven by a 12% increase in LUPKYNIS net product sales to $79.4M and a 54% jump in license, collaboration and royalty revenue to $4.3M.
  • EPS story Q3 EPS was flat YoY at $0.23, but declined sequentially from $0.28 in Q2, despite higher revenue, due to increased operating expenses and a lower tax rate.
  • One-off check Restructuring expense of $0 in Q3 2026, compared to $1.6M in Q3 2025.

The good

  • License, collaboration and royalty revenue grew 54% YoY
  • Net product sales grew 12% YoY
  • Cash and investments increased to $486.9M

The bad

  • Q3 net income declined 15.4% sequentially to $31.7M
  • Q3 diluted EPS declined 13.2% sequentially to $0.23
  • Cash flows from operating activities declined 44.3% sequentially to $46.4M

The ugly

  • Operating expenses increased 10.7% YoY to $48.3M, driven by higher R&D and SG&A

Open questions

  • What caused the sequential decline in net income and EPS despite revenue growth?
  • What drove the significant sequential decrease in cash flows from operating activities?
Full release

Aurinia Pharmaceuticals (AUPH) earnings release, October 30, 2026

Aurinia Pharmaceuticals Inc. (AUPH) · Form 8-K, Item 2.02 · Filed · SEC filing

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended

September 30, 2026 and Provides Update on Recent Business Progress

EDMONTON, Alberta – October 30, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on recent business progress.

Financial Results

• Total Revenue:

For the three and nine months ended September 30, 2026, total revenue was $83.7 million and $244.6 million, up 14% and 19%, respectively, from $73.5 million and $205.9 million, respectively, in the same periods of 2025. – Net Product Sales:

For the three and nine months ended September 30, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $79.4 million and $232.4 million, up 12% and 18%, respectively, from $70.6 million and $197.2 million, respectively, in the same periods of 2025. – License, Collaboration and Royalty Revenue:

For the three and nine months ended September 30, 2026, license, collaboration and royalty revenue was $4.3 million and $12.2 million, up 54% and 39%, respectively, from $2.8 million and $8.8 million, respectively, in the same periods of 2025.

• Net Income:

For the three and nine months ended September 30, 2026, net income before taxes was $38.7 million and $131.4 million, up 21% and 67%, respectively, from $32.0 million and $78.5 million, respectively, in the same periods of 2025. For the three and nine months ended September 30, 2026, net income was $31.7 million and $103.5 million, flat and up 35%, respectively, from $31.6 million and $76.4 million, respectively, in the same periods of 2025.

• Diluted Earnings per Share:

For the three and nine months ended September 30, 2026, diluted earnings per share was $0.23 and $0.76, flat and up 38%, respectively, from $0.23 and $0.55, respectively, in the same periods of 2025.

• Cash Flows from Operating Activities:

For the three and nine months ended September 30, 2026, cash flows from operating activities were $46.4 million and $131.5 million, up 4% and 46%, respectively, from $44.5 million and $90.0 million, respectively, in the same periods of 2025.

Cash Position

As of September 30, 2026, Aurinia had cash, cash equivalents, restricted cash and investments of $486.9 million, compared to $398.0 million at December 31, 2025. For the nine months ended September 30, 2026, cash outflows from financing activities were $53.2 million, which primarily included the repurchase of 5.0 million of the Company’s common shares for $74.9 million, partially offset by proceeds from issuance of common shares for equity awards, net of tax withholding payments, of $35.9 million.

2026 Total Revenue and Net Product Sales Guidance

Aurinia is increasing its total revenue guidance for 2026 from a range of $315 million to $325 million to a range of $325 million to $330 million. Aurinia is narrowing its net product sales guidance for 2026 from a range of $305 million to $315 million to a range of $310 million to $315 million.¹

Recent Development Progress

LUPKYNIS

Aurinia has recently initiated PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis. Belimumab is a B cell-activating factor (BAFF) inhibitor indicated for the treatment of both systemic lupus erythematosus (SLE) and lupus nephritis. Obinutuzumab is a CD20-directed cytolytic antibody indicated for the treatment of lupus nephritis. Anifrolumab is a type 1 interferon receptor antagonist indicated for the treatment of SLE. PRESERVE will investigate whether the multi-target approach of combining LUPKYNIS with these biologic agents improves outcomes in patients with lupus nephritis. Planned enrollment is approximately 150 patients across approximately 50 sites in the US. The Study’s primary endpoint is the proportion of patients achieving complete renal response (CRR) at 6 months.

Aritinercept

Aritinercept is a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Aurinia has now initiated clinical development of aritinercept in four potential indications.

About Aurinia

Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS®

(voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

Financial statements

Income Statement

Three Months Ended — (in thousands, except per share data)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Revenue
Net product sales79,41870,627232,393197,172
License, collaboration and royalty revenue4,2812,84112,2318,769
Total revenue83,69973,468244,624205,941
Operating expenses
Cost of revenue8,3068,17721,36623,866
Selling, general and administrative24,68426,18270,22172,539
Research and development16,6138,43537,13321,610
Restructuring1,647
Other (income) expense, net-1,267929-7,22214,604
Total operating expenses48,33643,723121,498134,266
Income from operations35,36329,745123,12671,675
Interest income4,2193,31611,12710,075
Interest expense-867-1,099-2,827-3,283
Net income before income taxes38,71531,962131,42678,467
Income tax expense7,01241127,9542,059
Net income31,70331,551103,47276,408
Earnings per share
Basic0.240.240.780.57
Diluted0.230.230.760.55
Shares used in computing earnings per share
Basic133,434131,808131,967135,163
Diluted135,173136,008135,346138,959

Balance Sheet

(in thousands)

September 30, 2026 – (Unaudited)December 31, 2025
Current assets:
Cash, cash equivalents and restricted cash46,14580,213
Short-term investments440,735317,784
Accounts receivable, net47,41441,454
Inventory43,72845,690
Prepaid expenses and deposits5,9155,746
Other current assets3,9491,080
Total current assets587,886491,967
Deferred tax assets, net170,652176,194
Finance right-of-use lease assets60,79573,865
Intangible assets, net3,1693,761
Property and equipment, net1,7372,111
Operating right-of-use lease assets1,3723,596
Other noncurrent assets9393
Total assets825,704751,587
Current liabilities:
Accounts payable3,0143,313
Accrued expenses63,29966,621
Finance lease liabilities, current portion16,15016,523
Deferred revenue10,4133,720
Operating lease liabilities, current portion1,8081,067
Other current liabilities1,3212,480
Total current liabilities96,00593,724
Finance lease liabilities, less current portion39,02852,322
Deferred tax benefits23,128
Deferred revenue, less current portion7,15712,648
Operating lease liabilities, less current portion1,6774,900
Other noncurrent liabilities1,1906,662
Total liabilities168,185170,256
Shareholders' equity
Common shares — no par value, unlimited shares authorized, 133,995 and 132,323 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively1,127,5031,120,035
Additional paid-in capital77,044111,263
Accumulated other comprehensive loss-1,132-599
Accumulated deficit-545,896-649,368
Total shareholders' equity657,519581,331
Total liabilities and shareholders' equity825,704751,587

Cash Flow

Nine Months Ended September 30, — (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:
Net income103,47276,408
Adjustments to reconcile net income to cash flows from operating activities:
Deferred income tax28,670
Share-based compensation8,0977,950
Amortization and depreciation14,49114,585
Foreign exchange (gain) loss on revaluation of Monoplant finance lease liability-2,6059,318
Net amortization of premiums and discounts on investments-6,141-7,844
Other, net-1,4984,852
Net changes in operating assets and liabilities:
Accounts receivable, net-5,9605,816
Inventory1,962-5,565
Prepaid expenses and other current assets-2,983940
Other noncurrent operating assets730
Accounts payable-2,172-2,973
Accrued expenses and other liabilities-4,372-17,777
Deferred revenue1,2024,150
Operating lease liabilities-670-600

Forward-Looking Statements... (truncated) Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, and on Aurinia’s website at www.auriniapharma.com.

Investor Inquiries ir@auriniapharma.com²

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Aurinia Pharmaceuticals earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.